NCT07602504 China Metastatic Liver Cancer Clinical Registry Cohort Database Status RECRUITING Phase N/A
NCT07587034 HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07537205 The Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Liver Cancer: Study and Protocol Status ENROLLING_BY_INVITATION Phase NA
NCT07447050 Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial Status RECRUITING Phase PHASE2
NCT07410494 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT07386639 Sex-Specific Machine Learning Models to Predict Distant Metastasis in Liver Cancer Status COMPLETED Phase N/A
NCT07362264 A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT07356531 Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer Status RECRUITING Phase NA
NCT07327489 Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies Status RECRUITING Phase N/A
NCT07325565 Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer Status RECRUITING Phase N/A
NCT07318051 Sample Collection for Ongoing Research and Product Evaluation Study Status RECRUITING Phase N/A
NCT07315633 An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer Status RECRUITING Phase N/A
NCT07295340 Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection Status RECRUITING Phase N/A
NCT07295275 Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection Status RECRUITING Phase N/A
NCT07233759 The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications. Status ACTIVE_NOT_RECRUITING Phase N/A
NCT07226063 Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer Status NOT_YET_RECRUITING Phase PHASE2